Risk factors

Perrigo faces significant risks from regulatory compliance, legal and antitrust scrutiny, and supply chain disruptions. Debt obligations totaling $3.6 billion and international operational exposure dominate the risk profile.

Primerica relies heavily on its independent contractor sales force to recruit clients and distribute insurance and investment products. The business faces extensive regulation across its life insurance, broker-dealer, advisory, and mortgage operations in the US and Canada. Operations depend on key information technology systems, data security, and stable relationships with third-party product manufacturers and reinsurers.

Prime Medicine faces substantial going concern doubt with an accumulated deficit of $687.2 million as of December 31, 2024. The company relies entirely on third-party licenses like Broad Institute and Beam Therapeutics without owning issued patents. Operations depend heavily on unproven Prime Editing technology and early-stage rare disease pipelines.

Commercial real estate loans are 64% of the portfolio and C&I loans are 28%, concentrating exposure in borrower cash flows and property values.

RPC Inc faces significant customer concentration, with a private E&P company providing 13 percent of 2024 revenues. The company is exposed to intense competition, skilled labor shortages, and stringent regulations on pressure pumping and hydraulic fracturing. A multi-year ERP implementation and concentrated insider control via the Rollins family shape its governance and operational risks.

Bitcoin price volatility, halving schedules, and network hash rate competition dominate Riot Platforms' operational risks. Massive electricity consumption, power facility dependencies, and emerging AI data center expansions dictate capital intensity. Regulatory uncertainty and cybersecurity threats across custody partners target core digital asset holdings.

Ridgepost Capital faces severe fee and capital-raising pressures if managed investments perform poorly or fail to find suitable targets.

Rapid7's risk profile is dominated by intense competition in SecOps, customer renewal dependencies for its Command Platform, and execution risks from restructuring, international scale, and recent acquisitions like Noetic Cyber.

Rapid Micro Biosystems faces persistent net losses and an accumulated deficit of $475.3 million as of December 31, 2024. Operations depend heavily on the commercial success of the Growth Direct platform and third-party single-source component suppliers. The company recently implemented an Operational Efficiency Program involving workforce reductions to manage cash.

Clinical-stage biotechnology company with no approved products, $1.4 billion accumulated deficit, and reliance on unproven AI-driven drug discovery platforms.

Rhythm Pharmaceuticals faces significant commercial, financial, and regulatory risks driven by its reliance on the success and market acceptance of IMCIVREE for rare genetic obesity. The company depends heavily on third-party manufacturers, licensed intellectual property from Ipsen and LGC, and the need for additional capital to fund clinical development.

Undeveloped Li-Metal battery technology with no prior commercial vehicle use creates massive uncertainty.